new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure

Experts are giving new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure.

Physicians already avoid giving rosiglitazone or pioglitazone (Actos) to patients with severe heart failure.

Now there's evidence that rosiglitazone increases cardiac risk in patients with LESS severe heart failure.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote